Búsqueda de un ensayo clínico
Otra(s) opcion(es) de búsqueda
43 Resultado(s)
Ensayo clínico en reclutamiento
= 
; Ensayos clínico en curso
= 
; Ensayo clínico finalizado
= 
; Financiado por un miembro del IRDiRC = 
; Estudio en el que participan integrantes de la ERN en al menos dos Estados miembros = 
Ensayo(s) clínico(s) nacional(es)
ALEMANIA
Berlin
ADDRESS: NOT PROVIDED - DE
IMAT-PV: A multicenter, randomized, placebo-controlled, double-blind proof of concept study to evaluate the efficacy and safety of the human normal immunoglobulin Intratect 5% for intravenous use as adjuvant therapy in patients with Pemphigus Vulgaris (Phase II) - DE -Prematurely Ended
Institution: Information not provided - DE
ALEMANIA
Berlin
ADDRESS: NOT PROVIDED - DE
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/ chromatography Purified (lGIV -C) as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients with Generalized Myasthenia Gravis -DE- terminated
Institution: Information not provided - DE
ALEMANIA
Berlin
ADDRESS: NOT PROVIDED - DE
An open-label, multicentre efficacy and safety study of I10E in patients with primary Immune ThrombocytoPenia (ITP) (Phase III) -DE-
Institution: Information not provided - DE
ALEMANIA
Berlin
BERLIN
Prospective, Open-label, Non-controlled, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NEWGAM) in Primary Immune Thrombocytopenia -DE-
Charité - Universitätsmedizin Berlin (CVK)
Institut für Transfusionsmedizin
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Clinical Study of Immune Globulin Subcutaneous (Human) (IGSC), 20% for the Evaluation of Efficacy, Safety, and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (Phase 2-3) - AT
Institution: Information not provided - AT
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
A clinical study of immune globulin subcutaneous (human) (IGSC), 20% for the evaluation of efficacy, safety, and pharmacokinetics in subjects with primary immunodeficiency diseases - BE
Institution: Information not provided - BE
BELGICA
VLAAMS BRABANT
LEUVEN
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis- BE
UZ Leuven - Campus Gasthuisberg
UZ Leuven
BELGICA
VLAAMS BRABANT
LEUVEN
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis (phase II) - BE (Completed)
UZ Leuven - Campus Gasthuisberg
UZ Leuven
ESPAÑA
Cataluña
BARCELONA
Ensayo clínico para evaluar la eficacia y seguridad de IGIV3I 10% Grifols (inmunoglobulina humana intravenosa) en pacientes diagnosticados con púrpura trombocitopénica inmune - ES (finalizado)
Hospital Universitari Vall d'Hebron
Servicio de Hematología y Hemoterapia
ESPAÑA
Cataluña
BARCELONA
Inmunoglobulina intravenosa para la prevención de crisis miasténica en pacientes con Miastenia Gravis antes de la timectomía y en la preparación de otros procedimientos quirúrgicos - ES (finalizado)
Hospital Universitari Vall d'Hebron
Servicio de Neurología
ESPAÑA
Cataluña
BARCELONA
Estudio de extensión abierto y multicéntrico para evaluar la seguridad y eficacia a largo plazo de IgPro20 como tratamiento de mantenimiento de la polineuropatía desmielinizante inflamatoria crónica (CIDP), en pacientes que hayan completado el estudio IgPro20_3003 - ES (finalizado)
Hospital Universitari Vall d'Hebron
Servicio de Neurología
ESPAÑA
Cataluña
BARCELONA
LIME Study: Estudio europeo aleatorizado, doble ciego, controlado con tratamiento comparador activo y de diseño cruzado que evalúa la seguridad y eficacia de una nueva formulación líquida y lista para usar de inmunoglobulina intravenosa humana al 10 % (I10E) en comparación con Kiovig® en pacientes con neuropatía motora multifocal - ES (finalizado)
Hospital de la Santa Creu i Sant Pau
Servicio de Neurología
ESPAÑA
Cataluña
BARCELONA
PRISM 2: Estudio internacional y multicéntrico sobre la eficacia y la seguridad de I10E en el tratamiento de mantenimiento de pacientes con polirradiculoneuropatía desmielinizante inflamatoria crónica: Extensión del estudio PRISM I10E-1302 - ES (finalizado)
Hospital de la Santa Creu i Sant Pau
Servicio de Neurología
ESPAÑA
Cataluña
L'HOSPITALET DE LLOBREGAT
The PATH Study: Estudio de fase III, aleatorizado, multicéntrico, en doble ciego, controlado con placebo y de grupos paralelos, para investigar la eficacia, seguridad y tolerabilidad de dos dosis diferentes de IgPro20 (inmunoglobulina subcutánea) en el tratamiento de la polineuropatía desmielinizante inflamatoria crónica (CIDP) - ES (finalizado)
Hospital Universitari de Bellvitge
Servicio de Neurología
ESPAÑA
Comunidad Valenciana
VALENCIA
PRISM 2: Estudio internacional y multicéntrico sobre la eficacia y la seguridad de I10E en el tratamiento de mantenimiento de pacientes con polirradiculoneuropatía desmielinizante inflamatoria crónica: Extensión del estudio PRISM I10E-1302 - ES (finalizado)
Hospital Universitario y Politécnico La Fe
Servicio de Neurología
ESPAÑA
Comunidad Valenciana
VALENCIA
PRISM: Estudio internacional, multicéntrico, sobre la eficacia y la seguridad de I10E en tratamientos iniciales y de mantenimiento de pacientes con polirradiculoneuropatía desmielinizante inflamatoria crónica - ES (finalizado)
Hospital Universitario y Politécnico La Fe
Servicio de Neurología
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio multicéntrico, abierto, de eficacia y seguridad de I10E en pacientes con trombocitopenia inmune primaria (TPI) - ES (finalizado)
Institution: Information not provided - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
RECLAIIM: Estudio para evaluar la eficacia, la seguridad y la farmacocinética de IgPro20 (inmunoglobulina subcutánea, Hizentra®) en adultos con dermatomiositis (DM) -ES
Institution: Information not provided - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio de fase II multicéntrico, aleatorizado, con doble enmascaramiento y controlado con placebo para evaluar la eficacia y seguridad de IgPro10 (inmunoglobulina intravenosa, Privigen®) en el tratamiento de adultos con esclerosis sistémica (finalizado)
Institution: Information not provided - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio multicéntrico, aleatorizado, prospectivo, abierto, para evaluar la seguridad y eficacia clínicas de la inmunoglobulina humana normal de administración intravenosa BT595 en pacientes con trombocitopenia inmune primaria (PTI) crónica (finalizado)
Institution: Information not provided - ES
ESTADOS UNIDOS
North Carolina
CLAYTON
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis (EE)
Grifols Therapeutics, Inc.
ESTADOS UNIDOS
North Carolina
CLAYTON
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis (EE)
Grifols Therapeutics, Inc.
ESTONIA
Tallinn
TALLINN
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis (EE)
East Tallinn Central Hospital
Clinic of Internal Medicine
ESTONIA
Tallinn
TALLINN
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis (EE)
East Tallinn Central Hospital
Clinic of Internal Medicine
FRANCIA
BOURGOGNE-FRANCHE-COMTE
BESANÇON
IGUS : Phase 2 multicentric study evaluating the efficacy of polyvalent intravenous immunoglobulins in idiopathic severe and refractory solar urticaria - FR
CHU de Besançon - Hôpital Jean Minjoz
Service de Dermatologie, maladies sexuellement transmissibles, allergologie et explorations cutanées
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A single-arm study to demonstrate the efficacy and safety of Privigen® in the treatment of subjects with chronic inflammatory demyelinating polyneuropathy (CIDP) (Phase III) - FR
Institution: Information not provided - FR
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
An open-label, multicentre efficacy and safety study of I10E in patients with primary Immune ThrombocytoPenia (ITP) (Phase III) - FR
Institution: Information not provided - FR
FRANCIA
ILE-DE-FRANCE
PARIS
EXCHANGE-IPF: Therapeutic Plasma Exchange, Rituximab and Intravenous Immunoglobulins for Severe Acute Exacerbation of Idiopathic Pulmonary Fibrosis Admitted in ICU: an Open, Randomized, Controlled Trial.
CHU Paris Nord-Val de Seine - Hôpital Xavier Bichat-Claude Bernard
Service de pneumologie A
FRANCIA
ILE-DE-FRANCE
PARIS
IGUS : Phase 2 multicentric study evaluating the efficacy of polyvalent intravenous immunoglobulins in idiopathic severe and refractory solar urticaria - FR
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis
Service de dermatologie
FRANCIA
ILE-DE-FRANCE
PARIS
Deimmunization of patients on transplantation waiting list using intra-venous immunoglobulins
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis
Service de néphrologie et transplantation rénale
FRANCIA
ILE-DE-FRANCE
PARIS
Follow-up study of IgIV efficacy in multifocal motor neuropathy with conduction block. Monocentric retrospective study.
Institut de Myologie - Hôpital Pitié-Salpêtrière
Unité clinique de pathologie neuromusculaire
FRANCIA
OCCITANIE
TOULOUSE
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis (Phase II) - FR
CHU de Toulouse - Hôpital Purpan
Département de neurologie
FRANCIA
PROVENCE-ALPES-COTE D'AZUR
NICE
A comparative, double-blind, randomised, multicentre efficacy and safety study of ClairYg® versus Tégéline® in maintenance treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (Phase III)
CHU de Nice - Hôpital Pasteur
Service Neurologie - Système Nerveux Périphérique et Muscles / Sclérose Latérale Amyotrophique
FRANCIA
PROVENCE-ALPES-COTE D'AZUR
NICE
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis (Phase II) - FR
CHU de Nice - Hôpital Pasteur
Service Neurologie - Système Nerveux Périphérique et Muscles / Sclérose Latérale Amyotrophique
ITALIA
ABRUZZO
PESCARA
Evaluation of the Safety and Efficacy of Standard Intravenous Immunoglobulins in Pregnant Women With Primary Cytomegalovirus Infection
Presidio Ospedaliero di Pescara
U.O.C. Malattie Infettive
ITALIA
LOMBARDIA
ROZZANO
PRISM 2 - International, multicentre, efficacy and safety study of I10E in the maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: extension of PRISM study I10E-1302 (phase III) - IT
IRCCS Istituto Clinico Humanitas
U.O. Malattie Neuromuscolari e Neuroimmunologia
ITALIA
LOMBARDIA
ROZZANO
An international, multicentre, efficacy and safety study of I10E in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy (phase III) - IT
IRCCS Istituto Clinico Humanitas
U.O. Malattie Neuromuscolari e Neuroimmunologia
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
A Randomised Phase II Double-blinded Placebo-controlled Trial of Intravenous Immunoglobulins and Rituximab in Patients With Antibody-associated Psychosis (SINAPPS2)
University of Cambridge
Department of Medicine
REINO UNIDO (EL)
Greater Manchester
ADDRESS: NOT PROVIDED - UK
European, randomised, double-blind, active comparator-controlled, cross-over, efficacy and safety study of a new 10% ready-to-use liquid human intravenous immunoglobulin (I10E) versus Kiovig® in patients with Multifocal Motor Neuropathy (Phase III) - UK
Institution: Information not provided - UK
REINO UNIDO (EL)
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A clinical study of immune globulin subcutaneous (human) (igsc), 20% for the evaluation of efficacy, safety, and pharmacokinetics in subjects with primary immunodeficiency diseases - UK (Completed)
Institution: Information not provided - UK
REINO UNIDO (EL)
Merseyside
LIVERPOOL
LIPS: A multi-centre (UK) double-blind randomised parallel group placebo controlled trial to evaluate the efficacy, safety, and tolerability of Intravenous Immunoglobulin (IVIg) 0.5g/kg plus standard treatment, versus matched placebo plus standard treatment in patients with longstanding Complex Regional Pain Syndrome (Phase II)
Clinical Sciences Building
Department of Translational Medicine
REINO UNIDO (EL)
Oxfordshire
OXFORD